Video

BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

Related Videos
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
C. Ola Landgren, MD, PhD
Robert M. Rifkin, MD
David Samuel Dicapua Siegel, MD
Marcella Ali Kaddoura, MD
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Shaji Kumar, MD
Related Content
The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/18

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Anitocabtagene Autoleucel in Multiple Myeloma | Image credit: © Nittaya – stock.adobe.com
December 11th 2024

Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

ASH Annual Meeting | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Lisaftoclax Plus Pd Yields High ORRs and Shows Encouraging Safety Profile in RRMM

Ide-cel in multiple myeloma
December 10th 2024

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma